leadf
logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma cancer drug to be focus of poster presentation at leading industry conference

Clevegen is precision cancer immunotherapy and information from the MATINS trial will be showcased at the European Society of Medical Oncology Congress, in Barcelona from September 27

Faron Pharmaceuticals Ltd -
The treatment, if successful, may ultimately be used as a standalone therapy or in combination with other immunotherapies

Faron Pharmaceuticals Oy (LON:FARN) said recent data from its Clevegen phase I/II study will be the subject of a poster presentation at a world-leading cancer conference.

Clevegen is precision cancer immunotherapy and information from the MATINS trial will be showcased at the European Society of Medical Oncology Congress, in Barcelona from September 27.

Faron said it will release further information from the poster and discussion slides to coincide with the start of the official session during which it features.

Cancers under investigation by Faron include cutaneous melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal.

All are known to host a significant number of Clever-1 positive tumour associated macrophages, which the Faron drug targets.

Part I of the early-stage trial deals with tolerability, safety, and dose escalation, allowing researchers to optimise how much of the drug is administered to patients.

The first expansion phase of part II will assess colorectal cancer patients, while part III of this early-stage trial will focus directly on the efficacy of Clevegen.

The treatment, if successful, may ultimately be used as a standalone therapy or in combination with other immunotherapies such as PD-1 inhibitors.

 

Quick facts: Faron Pharmaceuticals Ltd

Price: 410 GBX

AIM:FARN
Market: AIM
Market Cap: £191.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

1 week, 2 days ago

2 min read